65,437 trials
Advanced Solid Tumors · Metastatic Colon Cancer · Metastatic Breast Cancer
Primary: Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants
Chronic Venous Disease · CVD
Primary: Evaluation of Sensitivity (Sn) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist…
Post-acute Sequelae of SARS-CoV-2 Infection · Long COVID
Primary: Number of Participants With No, Mild, Moderate, or Severe Symptoms at Week 10 According to the Core Symptoms Severity Scale Score — 3; 4; 22; 17 Participants — p=0.903
Coronary Artery Disease
Primary: Initial Successful Hemostasis — 85; 88; 51; 74 Participants — p=0.906
Cervical Cancer · Endometrial Cancer · Esophageal Cancer
Primary: Number of Participants Who Had Adequate High-Quality Brachytherapy Implants Reported Per Strata (Four Body Sites) and Combined Overall — 27; 0; 0; 14 Participants
Medial or Lateral Instability Repairs/Reconstructions · Hallux Valgus Repairs · Achilles Tendon Repairs/Reconstructions
Primary: Number of Participants With Clinical Success of the Study Devices in the Extremity Over a Time Period of 6 Months After Intervention — 16; 1; 70; 1 Participants
Surgery · Surgical Blood Loss · Anemia
Primary: Total Hospital Costs — 23,667; 17,100 Dollars
Ann Arbor Stage II Follicular Lymphoma · Ann Arbor Stage II Marginal Zone Lymphoma · Ann Arbor Stage III Follicular Lymphoma
Primary: Progression Free Survival (PFS) — 71.2; 54.2 percentage of participants
Testing Protocol With Healthy Individuals for Feasibility
Primary: Neurofeedback Rating Scale — 5.7 units on a scale
Cardiovascular Disease · HIV
Primary: Change in Ambulatory Systolic Blood Pressure — 1.9; -10.7 mmHg — p=0.012
Upper GI; Lower GI; Gynecological
Primary: Number of Vessels With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale — 279 Vessels transected
Ulcerative Colitis
Primary: The Proportion of Patients Responders to Dex 21-P vs Placebo — 15; 1; 6; 11 Participants — p=<0.001
Macular Telangiectasia Type 2
Primary: The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24 — 0.111; 0.160 mm^2 — p=0.0186
Systemic Lupus Erythematosus (SLE)
Primary: Number of Participants With a SLE Responder Index (SRI-4) Response at Week 52 — 26; 29; 21; 35 Participants
Rhegmatogenous Retinal Detachment - Macula Off
Primary: Adverse Event (AE) Reporting — 3; 3; 3; 2 Participants